A cephalosporin bacterial degrading agent, its preparation method and application
By using cephalosporin degraders that target the bacterial penicillin-binding protein and ClpCP protease complex, the problem of cephalosporin antibiotic resistance has been solved, achieving direct elimination of drug-resistant bacteria and blocking cell wall biosynthesis, thus providing a novel anti-infective drug.
Patent Information
- Application Number
- CN202611181025.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-05
- Publication Date
- 2026-11-10
AI Technical Summary
Existing cephalosporin antibiotics face the problem of drug resistance, and traditional antibiotics, which rely on a single reversible inhibition mode, are not effective in dealing with the evolution of bacterial resistance.
We will design a cephalosporin-based bacterial degrader that targets bacterial penicillin-binding proteins (PBPs) and recruits the ClpCP protease complex to form a ternary complex, thereby directly and irreversibly clearing drug resistance-related target proteins and blocking bacterial cell wall biosynthesis.
It effectively overcomes drug resistance caused by target mutations or overexpression, improves the therapeutic effect on multidrug-resistant bacterial infections, and provides a molecular entity for novel anti-infective drugs.
Smart Images

Figure CN123062491A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical chemistry technology, specifically relating to a cephalosporin-type bacterial degrading agent, its preparation method, and its application. Background Technology
[0002] Cephalosporin antibiotics, as important β-lactam drugs widely used in clinical practice, play a crucial role in the treatment of bacterial infections. However, long-term and widespread use has led to increasingly serious problems of bacterial resistance. Many pathogenic bacteria hydrolyze drugs by expressing β-lactamases or evade drug binding through structural variations of target proteins (such as penicillin-binding proteins, PBPs), resulting in a significant decline in the efficacy of traditional antibiotics. Traditional antibiotics mainly rely on a "site-driven" reversible inhibition mode, a single pathway of action that proves ineffective against the continuously evolving resistance mechanisms of bacteria.
[0003] In recent years, targeted protein degradation technology has provided a novel approach to overcoming drug resistance. Traditional PROTAC molecules rely on the ubiquitin-proteasome system of eukaryotic cells and cannot function within bacteria. Designing BacPROTAC technology specifically for bacteria can recruit the bacterial-specific ClpCP protease complex to degrade bacterial target proteins, but specific degradative agents targeting the core proteins of cephalosporin-resistant bacteria have not yet been reported. Therefore, there is an urgent need to develop cephalosporin-targeted degradation molecules with high affinity and efficient degradation capabilities to directly and irreversibly eliminate resistance-related proteins, fundamentally overcoming the bottleneck of existing inhibitory antibacterial therapies. Summary of the Invention
[0004] In order to overcome the limitations of the prior art, the purpose of this invention is to provide a cephalosporin-type bacterial degrading agent, its preparation method and application, and to solve the problem of drug resistance easily generated by cephalosporin antibiotics.
[0005] To achieve the above objectives, the present invention employs the following technical solution: The first aspect of this invention discloses a cephalosporin-type bacterial degrading agent, which is a compound of Formula I or a pharmaceutically acceptable salt thereof, and a solvent compound, enantiomer, diastereomer, or mixture thereof in any proportion thereof, including racemic mixtures; the structural formula of the compound of Formula I is:
[0006] Wherein, the structural formula of A is The structural formula of L is n = 2, 4, 6 or 8, m = 0 or 1, R is a cephalosporin compound containing aminothiazole, and the amino group on the aminothiazole ring of R is amide bonded to the acyl carbonyl group of A or L.
[0007] Preferably, the cephalosporin compound containing aminothiazole is selected from the following compounds: .
[0008] In a second aspect, this invention discloses a method for preparing a cephalosporin-type bacterial degrading agent. When m=1, the method for preparing the cephalosporin-type bacterial degrading agent is as follows: using N-benzyloxycarbonyl-L-arginine as a raw material, its carboxyl group is protected with benzyl bromide to obtain compound I; compound I undergoes a phosphorylation reaction to obtain compound II; under acidic conditions, the protecting group on compound II is removed by palladium on carbon and hydrogen to obtain compound III; the α-amino group on compound III is protected with fluorenemethyloxycarbonyl chloride to obtain compound IV; and compound IV is used as a raw material... The compound undergoes an amide condensation reaction with Linker to give compound a; compound a is deprotected by a terminal tert-butyl protecting group to give compound b; the terminal carboxyl group of compound b undergoes an amide condensation reaction with a cephalosporin compound containing aminothiazole to give compound c; compound c is deprotected by a Fmoc protecting group on its side chain amino group to give compound d; the α-amino group of the arginine side chain in compound d forms an amide bond with acetic anhydride to give compound e; under Pd / C and hydrogen conditions, the trichloroethyl protecting group is removed to give a cephalosporin-based bacterial degrading agent. Among them, compound I is Compound II is Compound III is Compound IV is Linker is Compound a is Compound b is Compound C is Compound d is Compound e is n = 2, 4, 6 or 8.
[0009] The third aspect of this invention discloses a method for preparing a cephalosporin-based bacterial degrading agent. When m=0, the method for preparing the cephalosporin-based bacterial degrading agent is as follows: using N-benzyloxycarbonyl-L-arginine as a raw material, benzyl bromide is used to protect its carboxyl group to obtain compound I; compound I undergoes a phosphorylation reaction to obtain compound II; under acidic conditions, the protecting group on compound II is removed by palladium on carbon and hydrogen to obtain compound III; fluorene methoxycarbonyl chloride is used to protect the α-amino group on compound III to obtain compound IV; compound IV undergoes amide condensation with a cephalosporin compound containing aminothiazole to obtain compound c; compound c is deprotected by the Fmoc protecting group to obtain compound d; the α-amino group of the arginine side chain in compound d forms an amide bond with acetic anhydride to obtain compound e; the trichloroethyl protecting group is removed under Pd / C and hydrogen conditions to obtain the cephalosporin-based bacterial degrading agent. Among them, compound I is Compound II is Compound III is Compound IV is Compound C is Compound d is Compound e is .
[0010] A fourth aspect of the present invention discloses the application of a cephalosporin-type bacterial degrading agent in the preparation of anti-infective drugs.
[0011] A fifth aspect of the present invention discloses a pharmaceutical composition in which the above-mentioned cephalosporin-type bacterial degrading agent is used as an active ingredient.
[0012] Compared with the prior art, the present invention has the following beneficial effects: The present invention provides a cephalosporin-based bacterial degrading agent, which is composed of a cephalosporin-based ligand that targets bacterial penicillin-binding proteins (PBPs) and a phosphoarginine (pArg) functional fragment that specifically recruits bacterial ClpCP protease complexes. Based on this, an optimized linker is connected between the cephalosporin-based ligand and the phosphoarginine (pArg) functional fragment. Among them, 1) the cephalosporin ligands targeting bacterial penicillin-binding proteins contain cephalosporin derivative backbones, which can specifically recognize and bind to drug resistance-related target proteins in bacteria (such as mutated penicillin-binding proteins or β-lactamases), promoting the reduction of target protein levels; 2) the introduction of linkers with different chain lengths (including n=2, 4, 6, 8 and 0) facilitates the systematic regulation of molecular spatial conformation, flexibility and physicochemical properties, thereby optimizing the efficiency of target binding, intracellular exposure and induction of target protein reduction, and improving the scalability and iterability of molecular design; 3) the phosphoarginine functional fragment that specifically recruits bacterial ClpCP protease complexes can specifically recognize and bind to bacterial endogenous ClpCP protease complexes, thereby providing more sustained intervention in key processes of cell wall biosynthesis, which is different from the single mechanism of traditional cephalosporins that mainly relies on reversible inhibition. This cephalosporin-based bacterial degrader, developed through a strategy of targeted binding and induction of target protein reduction, overcomes the limitations of traditional cephalosporins that rely solely on "binding and inhibition." Upon entering bacteria, this molecule induces the formation of a ternary complex, directly and irreversibly clearing PBPs target proteins using the bacteria's endogenous degradation system. This blocks bacterial cell wall biosynthesis, demonstrating a synergistic effect of targeted inhibition and induced degradation. It effectively overcomes drug resistance caused by target mutations or overexpression, potentially reducing the likelihood of bacteria escaping drug action through target overexpression / mutation, completely eliminating the biological function of resistance proteins, and addressing the problem of decreased efficacy of traditional cephalosporins due to resistance protein expression or target mutations in drug-resistant bacteria. This provides an important molecular entity for the development of novel candidate drugs against multidrug-resistant bacterial infections.
[0013] The present invention provides a method for preparing a cephalosporin-type bacterial degrading agent, which uses readily available low-cost synthetic building blocks as raw materials and obtains the target product through common chemical reactions. The method avoids the use of high temperature, high pressure and highly toxic reagents, and can be carried out under relatively mild conditions. It has low equipment requirements and a relatively smaller environmental burden. Attached Figure Description
[0014] Figure 1 This is a graph showing the minimum inhibitory concentration of compound 12 of the present invention against MDRPA 264; Figure 2 This is a graph showing the minimum inhibitory concentration of compound 12 of the present invention against CR-EC 361; Figure 3This is a graph showing the minimum inhibitory concentration of compound 12 of the present invention against MDRAB 183; Figure 4 The diagram shows the minimum inhibitory concentration of compound 17 of the present invention against MRSA ATCC 43300. Figure 5 This is a graph showing the minimum inhibitory concentration of compound 17 of the present invention against MDRSA 171; Figure 6 The figure shows the effect of compound 17 of the present invention on the expression level of PBP2a protein in MRSA ATCC 43300; the left figure is a Western blot gel, and the right figure is the Western blot quantitative analysis result. Detailed Implementation
[0015] To enable those skilled in the art to understand the features and effects of the present invention, the following description and definitions are only general descriptions of the terms and expressions mentioned in the specification. Unless otherwise specified, all technical and scientific terms used herein have the ordinary meaning understood by those skilled in the art regarding the present invention, and in case of conflict, the definitions in this specification shall prevail.
[0016] The theories or mechanisms described and disclosed herein, whether right or wrong, should not in any way limit the scope of the invention, that is, the contents of the invention can be implemented without being limited by any particular theory or mechanism.
[0017] In this document, all features defined by numerical ranges or percentage ranges, such as numerical values, quantities, contents, and concentrations, are for the sake of brevity and convenience only. Accordingly, descriptions of numerical ranges or percentage ranges should be considered as covering and specifically disclosing all possible sub-ranges and individual numerical values (including integers and fractions) within those ranges.
[0018] In this article, unless otherwise specified, “contains,” “includes,” “containing,” “has,” or similar terms cover the meanings of “composed of” and “mainly composed of,” for example, “A contains a” covers the meanings of “A contains a and others” and “A contains only a.”
[0019] For the sake of brevity, not all possible combinations of the technical features in each implementation scheme or embodiment are described herein. Therefore, as long as there is no contradiction in the combination of these technical features, the technical features in each implementation scheme or embodiment can be combined arbitrarily, and all possible combinations should be considered within the scope of this specification.
[0020] Unless otherwise specified, “L” in the general formula refers to the linker.
[0021] This invention provides a cephalosporin-based bacterial degrading agent (BacPROTACs), which is a compound of Formula I or a pharmaceutically acceptable salt thereof, and a solvent compound, enantiomer, diastereomer, or mixture thereof in any proportion thereof, including racemic mixtures. The structural formula of the compound of Formula I is:
[0022] Wherein, the structural formula of A is The structural formula of L is n = 2, 4, 6 or 8, m = 0 or 1, R is a cephalosporin compound containing aminothiazole, and the amino group on the aminothiazole ring of R is amide bonded to the acyl carbonyl group of A or L.
[0023] Furthermore, R is selected from the following compounds:
[0024]
[0025] The method for preparing cephalosporin-type bacterial degrading agents provided by the present invention includes the following steps: 1. When m=1, the preparation method of cephalosporin-type bacterial degrading agents is as follows: 1) Preparation of compound IV
[0026] Using N-benzyloxycarbonyl-L-arginine as a starting material, its carboxyl group was protected with benzyl bromide to obtain compound I; compound I was phosphorylated with bis(trichloroethyl)phosphoryl chloride to obtain compound II; under acidic conditions of trifluoroacetic acid and acetic acid, the protecting group on compound II was removed by palladium on carbon (Pd / C) and hydrogen to obtain compound III; finally, the α-amino group on compound III was protected with fluorenemethyloxycarbonyl chloride to obtain compound IV.
[0027] 2) Reaction with Linker via amide condensation
[0028] Using the synthesized compound IV as a raw material, an amide condensation reaction was carried out with Linker to obtain the corresponding compounds a1-a4; Where n = 2, 4, 6 or 8.
[0029] 3) Determination of tert-butyl protecting group
[0030] The obtained compounds a1-a4 were deprotected with trifluoroacetic acid to obtain the corresponding compounds b1-b4; Where n = 2, 4, 6 or 8.
[0031] 4) Reaction with cephalosporin compounds via amide condensation.
[0032] Using compounds b1-b4 as raw materials, amide condensation reactions were carried out with cephalosporin compounds containing aminothiazole to obtain compound c (corresponding to compounds c2-c5, c7-c10, c12-c15, c17-c20, c22-c25). The Linker length is n=2, 4, 6 or 8, and the cephalosporin compounds containing aminothiazole are ceftazidime, cefixime, cefotaxime, cefdinir or cefazolin.
[0033] 5) Deprotection of Fmoc groups
[0034] Using DMF as a solvent, compound c was deprotected with 20% piperidine to obtain compound d; The PEG chain length is n=2, 4, 6 or 8, and R is ceftazidime, cefixime, cefotaxime, cefdinir or cefazolin.
[0035] 6) Acylation reaction
[0036] Using compound d as a starting material, acetic anhydride is used to acylate the compound to obtain compound e; Wherein, the PEG chain length is n=2, 4, 6 or 8, R is ceftazidime, cefixime, cefotaxime, cefdinir or cefazolin, d corresponds to compounds d2-d5, d7-d10, d12-d15, d17-d20 or d22-d25, and the structural formula of d2-d5 is as follows. The structural formulas for d7-d10 are: The structural formulas for d12-d15 are: The structural formulas for d17-d20 are: The structural formula of d22-d25 is .
[0037] 7) Deprotection of trichloroethyl group
[0038] Compound e was dissolved in ammonium carbonate buffer solution, anhydrous ethanol was added, and the trichloroethyl protecting group of compound e was removed under a hydrogen atmosphere using Pd / C as a catalyst to obtain the target compounds (corresponding compounds 2-5, 7-10, 12-15, 17-20, 22-25). In this context, the PEG chain length is n = 2, 4, 6, or 8, and compound e corresponds to compounds e2-e5, e7-e10, e12-e15, e17-e20, and e22-e25. The structural formula of e2-e5 is... The structural formulas for e7-e10 are: The structural formulas for e12-e15 are: The structural formulas for e17-e20 are: The structural formulas for e22-e25 are: .
[0039] 2. When m=0, the preparation method of cephalosporin-type bacterial degrading agents is as follows: The difference from the aforementioned preparation method is that steps 2) and 3) are omitted. After step 1), compound IV directly undergoes amide condensation with five cephalosporin compounds containing aminothiazole to obtain compound c (corresponding to compounds c1, c6, c11, c16, and c21); the Fmoc protecting group is removed to obtain compound d (compounds d1, d6, d11, d16, and d21); acylation reaction is performed to obtain compound e (compounds e1, e6, e11, e16, and e21); the trichloroethyl protecting group is removed to obtain target compounds 1, 6, 11, 16, and 21. Wherein, the structural formula of c1 is The structural formula of c6 is The structural formula of c11 is The structural formula of c16 is The structural formula of c21 is The structural formula of d1 is The structural formula of d6 is The structural formula of d11 is The structural formula of d16 is The structural formula of d21 is The structural formula of e1 is The structural formula of e6 is The structural formula of e11 is The structural formula of e16 is The structural formula of e21 is .
[0040] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Furthermore, it should be understood that after reading this description, those skilled in the art can make various alterations or modifications to the invention, and these equivalent forms also fall within the scope defined in this application.
[0041] The following examples use instruments and equipment conventional in the art. Experimental methods in the following examples, unless otherwise specified, are generally performed under conventional conditions or as recommended by the manufacturer. All raw materials used in the following examples are conventional commercially available products with specifications conventional in the art. In this specification and the following examples, unless otherwise specified, "%" represents weight percentage, "parts" represents parts by weight, and "ratio" represents weight proportion.
[0042] I. Specific Examples of Synthesizing Compounds 1-25 The structural formulas of representative compounds of this invention are shown below:
[0043]
[0044]
[0045] Examples of the synthesis of the above compounds are given below.
[0046] Example 1 Compound 1: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 2-acetamido-5-(3-phosphonoguanidinyl)pentamido)thiazo-4-yl)-2-(((2-carboxypropyl-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-on-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid ester Step 1: Synthesis of Compound IV
[0047] N-Benzyloxycarbonyl-L-arginine (3.08 g, 10 mmol) was placed in a round-bottom flask, and N-methylpyrrolidone (NMP, 40 mL) was added. Nitrogen gas was purged for 15 min to remove air. The mixture was heated in an oil bath to 90 °C until the substrate was completely dissolved, and then the reaction system was cooled to room temperature. Benzyl bromide (BnBr, 1.31 mL, 11 mmol) was then slowly added dropwise. The reaction was carried out under nitrogen protection and in the dark with magnetic stirring at room temperature, and the reaction progress was monitored by TLC (thin-layer chromatography). After 5 h, the reaction was complete, and most of the NMP was removed by concentration under reduced pressure. The residue was dissolved in ethyl acetate, and the organic phase was washed successively with saturated sodium chloride solution and distilled water. After drying with anhydrous sodium sulfate, the mixture was rotary evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 20:1) to give compound I (3.27 g, yield 82.07%). Compound I (1.99 g, 5 mmol), bis(trichloroethyl)phosphoryl chloride (2.28 g, 6 mmol), and triethylamine (764.48 μL, 5.5 mmol) were dissolved in 30 mL of acetonitrile. The reaction was carried out with magnetic stirring at room temperature and monitored by TLC. After 7 h, the reaction was completed. Most of the organic solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 10:1) and dried to give compound II (3.00 g, yield 80.95%). Compound II (2.96 g, 4 mmol) was dissolved in 20 mL of trifluoroacetic acid and 20 mL of acetic acid, and then 500 mg of Pd / C (10% Pd) was added. The reaction was stirred overnight at room temperature under a hydrogen atmosphere. The reaction progress was monitored by TLC (thin-layer chromatography). After the starting material was completely consumed, palladium on carbon was filtered off, and most of the organic solvent was removed by concentration under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 8:1) and dried to give compound III (1.91 g, yield 92.37%). Compound III (1.81 g, 3.5 mmol), triethylamine (1 mL), and Fmoc-Cl (1.18 g, 4.55 mmol) were placed in a reactor, dissolved in acetonitrile (20 mL), and reacted overnight at room temperature with stirring. The reaction progress was monitored by TLC. After the reaction was completed, the acetonitrile was removed by concentration under reduced pressure. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 10:1), dried, and yielded compound IV (2.27 g, yield 87.74%).
[0048] Step 2: Synthesis of Compound 1 (1) Preparation of intermediate c1 It should be noted that since the linker length of compound 1 is 0, compound IV directly condenses with ceftazidime during the reaction process, as follows:
[0049] Compound IV (739.18 mg, 1 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (HATU, 456.29 mg, 1.2 mmol), and N,N-diisopropylethylamine (DIEA, 348.36 μL, 2 mmol) were dissolved in 5 mL of N,N-dimethylformamide (DMF) and stirred at room temperature for 15 min (to activate the carboxyl group of compound IV). Then, ceftazidime (610.23 mg, 1.1 mmol) was added, and the mixture was stirred magnetically at room temperature. The reaction progress was monitored by TLC (thin-layer chromatography). After the reaction was completed, an appropriate amount of water was added, and the mixture was extracted three times with ethyl acetate (20 mL each time). The organic phases were combined. Anhydrous sodium sulfate was added to the organic phase for drying. After filtration, the organic solvent was removed by vacuum concentration. The crude product was separated by silica gel column chromatography (dichloromethane:methanol = 5:1) and dried to obtain intermediate compound c1 (1.14 g, yield 89.92%).
[0050] (2) Preparation of intermediate d1
[0051] Compound c1 (1.01 g, 0.8 mmol) was dissolved in 5 mL of DMF, followed by the addition of 5 mL of 20% piperidine. The reaction was carried out with magnetic stirring at room temperature, and the reaction progress was monitored by TLC. After the reaction was completed, the system was diluted with an appropriate amount of water, extracted three times with ethyl acetate, and the organic phases were combined. The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the crude product was separated by silica gel column chromatography (dichloromethane:methanol = 2:1). After drying, intermediate d1 (724.35 mg, yield 86.60%) was obtained.
[0052] (3) Preparation of intermediate e1
[0053] Compound d1 (627.30 mg, 0.6 mmol), DIEA (125.41 μL, 0.72 mmol), and acetic anhydride (113.43 μL, 1.2 mmol) were dissolved in 10 mL NMP. The mixture was magnetically stirred at room temperature, and the reaction was monitored by TLC. After the reaction was complete, the reaction solution was slowly added dropwise to ice water to quench the acetic anhydride. The pH was then adjusted to weakly alkaline with saturated sodium bicarbonate solution, followed by multiple extractions with ethyl acetate-water. The organic phase was washed with saturated sodium chloride solution, and an appropriate amount of anhydrous sodium sulfate was added to the organic phase to remove water. The organic phase was removed by rotary evaporation under reduced pressure. The crude product was separated by silica gel column chromatography (dichloromethane:methanol = 5:1), dried, and intermediate e1 (585.8 mg, yield 89.78%) was obtained.
[0054] (4) Preparation of compound 1
[0055] Compound e1 (543.77 mg, 0.5 mmol) was dissolved in 5 mL of ammonium carbonate buffer solution, and 5 mL of ethanol and 350 mg of palladium on carbon were added. The reaction was carried out under a hydrogen atmosphere with magnetic stirring at room temperature and atmospheric pressure, and the reaction progress was monitored by TLC. After the reaction was completed, palladium on carbon was filtered off, and ethanol was removed by concentration under reduced pressure. The residue was dissolved in dichloromethane, and the organic phase was washed successively with saturated sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was removed by concentration under reduced pressure, and the crude product was separated by silica gel column chromatography (dichloromethane:methanol = 1:1), dried, and the target compound 1 (387.70 mg, yield 94.01%) was obtained.
[0056] 1 H NMR (400 MHz, DMSO- d 6) δ 12.64 (s, 1H), 12.41 (s, 1H), 9.07 – 9.04 (m, 2H), 8.75 (s, 1H), 8.69 – 8.61 (m, 1H), 8.26 (dd, J = 8.0, 6.0 Hz, 2H),8.18 (s, 2H), 8.01 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 8.2 Hz, 1H), 6.95 (s, 1H), 6.32 (t, J = 3.3 Hz, 1H), 5.87 (dd, J = 8.1, 6.8 Hz, 1H), 5.76 – 5.70 (m, 2H), 5.11 (d, J = 6.8 Hz, 1H), 5.03 (s, 1H), 4.41 – 4.32 (m, 1H), 3.83 – 3.65 (m,2H), 3.26 – 3.16 (m, 2H), 1.96 – 1.85 (m, 4H), 1.81 – 1.71 (m, 1H), 1.68 –1.55 (m, 2H), 1.43 (s, 6H). 13 C NMR (101 MHz, DMSO- d6) δ 175.84, 173.13, 172.79, 170.49, 167.90,167.34, 161.57, 159.93, 150.74, 146.43, 144.75, 143.50, 128.24, 123.51,120.67, 112.54, 80.91, 61.47, 60.73, 59.53, 53.31, 41.96, 30.29, 28.80,25.95, 24.07, 22.48. Example 2 Compound 2: (6 R 7 R )-7-(2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14-dioxa-2,8-diazaheptadecane-17-amino)thiazo-4-yl)-2-(((2-carboxypropyl-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-on-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid ester (1) Preparation of intermediate a2
[0057] Compound IV (739.19 mg, 1 mmol), HATU (456.29 mg, 1.2 mmol), and DIEA (348.36 μL, 2 mmol) were dissolved in 5 mL of DMF and stirred at room temperature for 15 min. Then, tert-butyl 3-(2-(2-aminoethoxy)ethoxy)propionate (256.64 mg, 1.1 mmol) was added, and the mixture was magnetically stirred at room temperature. The reaction was monitored by TLC. After the reaction was complete, an appropriate amount of water was added, and the mixture was extracted three times with ethyl acetate (20 mL each time). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the organic solvent. The crude product was separated by silica gel column chromatography (DCM:methanol = 10:1) and dried under reduced pressure to give intermediate compound a2 (781.02 mg, yield 81.83%).
[0058] (2) Preparation of intermediate b2
[0059] Compound a2 (763.58 mg, 0.8 mmol) was dissolved in 3 mL of dichloromethane (DCM), followed by the addition of 2 mL of trifluoroacetic acid (TFA). The reaction was stirred at room temperature, and the reaction progress was monitored by TLC. After the reaction was completed, most of the solvent was removed by concentration under reduced pressure. The crude product was separated by silica gel column chromatography (dichloromethane:methanol = 8:1) and dried to give compound b2 (731.87 mg, yield 87.91%).
[0060] (3) Preparation of intermediate c2
[0061] Intermediate b2 (628.86 mg, 0.7 mmol), HATU (319.40 mg, 0.84 mmol), and DIEA (182.89 μL, 1.05 mmol) were dissolved in 5 mL of DMF and stirred at room temperature for 15 min. Ceftazidime (420.86 mg, 0.77 mmol) was then added, and the reaction was monitored by TLC. After the reaction was complete, an appropriate amount of water was added, and the mixture was extracted three times with ethyl acetate. The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the organic solvent. The crude product was separated by silica gel column chromatography (dichloromethane:methanol = 5:1) and dried to give compound c2 (837.74 mg, yield 83.87%).
[0062] (4) Preparation of intermediate d2
[0063] Compound C2 (713.47 mg, 0.5 mmol) was dissolved in 5 mL of DMF, followed by the addition of 5 mL of 20% piperidine. The reaction was carried out with magnetic stirring at room temperature, and the reaction progress was monitored by TLC. After the reaction was completed, the system was diluted with an appropriate amount of water, extracted three times with ethyl acetate, and the organic phases were combined. The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the crude product was separated by silica gel column chromatography (dichloromethane:methanol = 2:1). After drying, intermediate D2 (526.30 mg, yield 87.38%) was obtained.
[0064] (5) Preparation of intermediate e2
[0065] Compound d2 (481.88 mg, 0.4 mmol), DIEA (83.61 μL, 0.48 mmol), and acetic anhydride (75.62 μL, 0.8 mmol) were dissolved in 10 mL NMP. The mixture was magnetically stirred at room temperature, and the reaction was monitored by TLC. After the reaction was complete, the reaction solution was slowly added dropwise to ice water to quench the acetic anhydride. The pH was then adjusted to weakly alkaline with saturated sodium bicarbonate solution, followed by multiple extractions with ethyl acetate-water. The organic phase was washed with saturated sodium chloride solution, and an appropriate amount of anhydrous sodium sulfate was added to the organic phase to remove water. The organic phase was removed by rotary evaporation under reduced pressure. The crude product was separated by silica gel column chromatography (dichloromethane:methanol = 5:1), dried, and the intermediate e2 (448.61 mg, yield 89.95%) was obtained.
[0066] (6) Synthesis of compound 2
[0067] Compound e2 (374.02 mg, 0.3 mmol) was dissolved in 5 mL of ammonium carbonate buffer solution, and 5 mL of ethanol and 350 mg of palladium on carbon were added. The reaction was carried out under a hydrogen atmosphere with magnetic stirring at room temperature and atmospheric pressure, and the reaction progress was monitored by TLC. After the reaction was completed, palladium on carbon was filtered off, and ethanol was removed by concentration under reduced pressure. The crude product was separated by silica gel column chromatography (dichloromethane:methanol = 1:1), dried, and the target compound 2 (205.94 mg, yield 69.77%) was obtained.
[0068] 1 H NMR (400 MHz, DMSO- d 6) δ 12.13 (s, 1H), 9.86 (s, 1H), 9.11 – 8.99 (m, 2H), 8.79 (s, 1H), 8.64 – 8.52 (m, 1H), 8.17 (dd, J = 8.1, 6.4 Hz, 2H),8.14 (s, 2H), 8.09 (d, J = 8.3 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 4.6Hz, 1H), 6.90 (s, 1H), 6.31 (t, J = 3.7 Hz, 1H), 5.83 (dd, J = 8.1, 6.6 Hz, 1H),5.78 – 5.70 (m, 2H), 5.16 (d, J= 6.2 Hz, 1H), 5.13 (s, 1H), 4.13 – 4.08 (m,1H), 3.81 (d, J = 15.0 Hz, 1H), 3.72 (s, 1H), 3.69 – 3.65 (m, 2H), 3.58 – 3.50(m, 2H), 3.45 – 3.38 (m, 2H), 3.26 – 3.18 (m, 2H), 2.68 (t, J = 5.9 Hz, 2H),2.08 – 1.93 (m, 1H), 1.91 (s, 3H), 1.79 – 1.68 (m, 2H), 1.65 – 1.54 (m, 1H),1.42 (s, 6H). 13 C NMR (101 MHz, DMSO- d 6) δ 175.83, 173.72, 172.79, 171.31, 170.68,167.95, 167.31, 163.13, 158.22, 150.91, 146.46, 144.72, 142.98, 128.65,123.53, 120.63, 112.67, 80.91, 69.03, 65.84, 61.48, 60.76, 59.53, 52.38,37.93, 37.75, 36.57, 30.29, 28.71, 25.89, 24.06, 22.36. Example 3 Compound 3: (6 R 7 R )-7-(2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20-tetraoxa-2,8-diazatoritriane-23-amino)thiazo-4-yl)-2-(((2-carboxypropyl-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-on-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid ester: The preparation method is the same as in Example 2, except that tert-butyl 3-(2-(2-aminoethoxy)ethoxy)propionate is replaced with 1-amino-3,6,9,12-tetraoxapentadecan-15-oate. The yield of compound 3 was 38.1%.
[0069] 1H NMR (400 MHz, DMSO- d 6) δ 9.79 (s, 1H), 9.08 – 9.02 (m, 2H), 8.86(s, 1H), 8.70 – 8.61 (m, 1H), 8.19 – 8.15 (m, 2H), 8.06 (d, J = 6.0 Hz, 3H),7.91 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.01 – 6.95 (m, 2H), 6.32 (t, J = 3.3 Hz, 1H), 5.83 (dd, J = 8.1, 6.9 Hz, 1H), 5.79 – 5.69 (m, 2H), 5.19 (d, J =6.8 Hz, 1H), 5.11 (s, 1H), 4.14 – 4.06 (m, 1H), 3.81 (d, J = 14.8 Hz, 1H), 3.74– 3.56 (m, 17H), 3.28 – 3.06 (m, 4H), 2.68 (t, J = 5.8 Hz, 2H), 2.30 (s, 3H),2.05 – 1.94 (m, 1H), 1.81 (s, 3H), 1.79 – 1.69 (m, 2H), 1.67 – 1.55 (m, 1H),1.42 (s, 6H). 13 C NMR (101 MHz, DMSO- d 6) δ 191.41, 175.84, 173.67, 171.39, 170.42,167.31, 166.84, 163.14, 158.29, 150.94, 146.43, 144.76, 142.96, 140.15,128.64, 116.24, 112.61, 80.45, 70.79, 70.67, 70.61, 69.71, 69.51, 69.09,65.97, 62.31, 60.53, 59.42, 52.34, 37.88, 37.08, 36.52, 30.14, 28.75, 28.61,25.43, 24.19, 22.42. Example 4 Compound 4: (6 R 7 R )-7-(2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26-hexaoxa-2,8-diazaoctacosane-28-amino)thiazo-4-yl)-2-(((2-carboxypropyl-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-on-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid ester: The preparation method is the same as in Example 2, except that tert-butyl 3-(2-(2-aminoethoxy)ethoxy)propionate is replaced with 1-amino-3,6,9,12,15,18-hexaoxane-21-oate. The yield of compound 4 was 22.3%.
[0070] 1 H NMR (400 MHz, DMSO- d 6) δ 9.83 (s, 1H), 9.08 – 9.02 (m, 2H), 8.79 (s, 1H), 8.68 – 8.59 (m, 1H), 8.19 – 8.15 (m, 2H), 8.13 – 8.06 (m, 3H), 7.96(d, J = 8.1 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.01 – 6.95 (m, 2H), 6.57 (t, J =3.9 Hz, 1H), 5.83 (dd, J = 8.2, 6.4 Hz, 1H), 5.74 – 5.66 (m, 2H), 5.19 (d, J =6.2 Hz, 1H), 5.11 (s, 1H), 4.14 – 4.06 (m, 1H), 3.81 (d, J = 14.1 Hz, 1H), 3.74– 3.56 (m, 26H), 3.30 – 3.12 (m, 4H), 2.68 (t, J= 5.8 Hz, 2H), 2.30 (s, 3H), 2.05 – 1.94 (m, 1H), 1.82 (s, 3H), 1.79 – 1.69 (m, 2H), 1.67 – 1.55 (m, 1H), 1.46 (s, 6H). 13 C NMR (101 MHz, DMSO- d 6) δ 191.51, 175.15, 173.53, 171.38, 170.69,167.32, 166.94, 161.57, 157.29, 150.64, 146.73, 144.72, 143.45, 140.45,128.64, 116.20, 112.69, 80.99, 70.79, 70.69, 70.61, 69.70, 69.51, 69.09,65.97, 62.31, 60.63, 59.42, 52.34, 37.25, 37.00, 36.47, 30.29, 28.71, 28.69, 25.89, 24.97, 22.68. Example 5 Compound 5: (6 R 7 R )-7-(2-(2-(( S Preparation of octyl-6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26,29,32-octoxy-2,8-diazatritane-3,4-amino)thiazo-4-yl)-2-(((2-carboxypropyl-2-yl)oxy)imino)acetamido)-8-oxo-3-(pyridin-1-on-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]octyl-2-en-2-carboxylic acid ester: The preparation method is the same as in Example 2, except that tert-butyl 3-(2-(2-aminoethoxy)ethoxy)propionate is replaced with 1-amino-3,6,9,12,15,18,21,24-octaoxaheptadecane-27-oate. The yield of compound 5 was 10.9%.
[0071] 1 H NMR (400 MHz, DMSO- d6) δ 12.33 (s, 1H), 9.45 (s, 1H), 9.13 – 9.02 (m, 2H), 8.65 (s, 1H), 8.60 – 8.52 (m, 1H), 8.19 – 8.11 (m, 4H), 7.91 (d, J =8.1 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.03 – 6.92 (m, 2H), 6.32 (t, J = 3.5 Hz, 1H), 5.83 (dd, J = 8.3, 6.7 Hz, 1H), 5.74 – 5.68 (m, 2H), 5.19 (d, J = 6.2 Hz,1H), 5.03 (s, 1H), 4.14 – 4.06 (m, 1H), 3.81 (d, J = 14.2 Hz, 1H), 3.73 – 3.71(m, 3H), 3.70 – 3.67 (m, 19H), 3.66 – 3.62 (m, 9H), 3.62 – 3.58 (m, 2H), 3.32– 3.20 (m, 4H), 2.68 (t, J = 5.8 Hz, 2H), 2.30 (s, 3H), 2.05 – 1.88 (m, 4H), 1.79 – 1.54 (m, 3H), 1.34 (s, 6H). 13 C NMR (101 MHz, DMSO- d 6) δ 191.91, 175.85, 173.77, 171.38, 170.69,167.31, 166.84, 161.57, 158.29, 150.94, 146.43, 144.76, 143.35, 140.15,128.64, 116.20, 112.69, 80.99, 70.79, 70.69, 70.61, 69.70, 69.51, 69.09,65.97, 62.31, 60.53, 59.42, 52.34, 37.63, 37.36, 36.29, 30.14, 28.68, 28.57, 25.32, 24.07, 22.62. Example 6 Compound 6: (6R 7 R )-7-(( Z )-2-(2-(( S Preparation of 2-acetamido-5-(3-phosphonoguanidinyl)pentamido)thiazo-4-yl)-2-((carboxymethoxy)imino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method was the same as in Example 1, except that cefixime was used instead of ceftazidime. The yield of compound 6 was 87.6%.
[0072] 1 H NMR (400 MHz, DMSO- d 6) δ 12.64 (s, 1H), 12.52 (s, 1H), 12.31 (s,1H), 8.86 (s, 1H), 8.42 (s, 2H), 7.96 (d, J = 8.2 Hz, 1H), 7.78 (d, J = 8.1 Hz,1H), 6.96 (s, 1H), 6.92 – 6.81 (m, 1H), 6.32 (t, J = 3.3 Hz, 1H), 5.95 (dd, J =16.3, 1.8 Hz, 1H), 5.74 (dd, J = 8.0, 6.8 Hz, 1H), 5.69 (dd, J = 10.9, 1.9 Hz, 1H), 5.43 (d, J = 6.8 Hz, 1H), 5.15 (s, 1H), 4.80 (s, 2H), 4.39 – 4.30 (m, 1H), 3.77 – 3.58 (m, 2H), 3.28 – 3.15 (m, 2H), 1.97 – 1.84 (m, 4H), 1.80 – 1.68(m, 1H), 1.67 – 1.57 (m, 2H). 13 C NMR (101 MHz, DMSO- d6) δ 175.48, 173.14, 170.36, 167.32, 167.11,165.82, 161.85, 159.44, 146.66, 142.78, 130.19, 127.63, 126.50, 124.70,112.27, 70.60, 67.28, 60.69, 53.31, 46.96, 28.80, 25.23, 24.95, 22.53. Example 7 Compound 7: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14-dioxa-2,8-diazaheptadecane-17-amino)thiazo-4-yl)-2-((carboxymethoxy)imino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 2, except that cefixime is used instead of ceftazidime. The yield of compound 7 was 59.4%.
[0073] 1 H NMR (400 MHz, DMSO- d 6) δ 12.55 (s, 1H), 12.52 (s, 1H), 12.19 (s,1H), 9.86 (s, 1H), 8.70 (s, 1H), 8.14 (s, 2H), 7.81 – 7.71 (m, 2H), 7.13 –6.79 (m, 3H), 6.32 (t, J = 3.3 Hz, 1H), 6.17 – 5.91 (m, 3H), 5.14 (d, J = 6.8 Hz,1H), 5.13 (s, 1H), 4.85 (s, 2H), 4.22 – 3.98 (m, 1H), 3.80 – 3.69 (m, 3H), 3.67 – 3.56 (m, 6H), 3.30 – 3.25 (m, 2H), 3.23 – 3.17 (m, 2H), 2.68 (t, J = 5.8Hz, 2H), 2.04 – 1.96 (m, 1H), 1.92 (s, 3H), 1.78 – 1.57 (m, 3H). 13 C NMR (101 MHz, DMSO- d 6) δ 174.77, 173.43, 171.28, 170.19, 167.30,167.21, 165.89, 161.88, 158.27, 146.54, 143.55, 134.19, 127.33, 126.52,124.71, 112.60, 70.60, 69.70, 69.59, 69.19, 65.87, 60.28, 60.19, 52.34,37.71, 37.28, 36.57, 28.88, 28.06, 25.17, 22.69. Example 8 Compound 8: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20-tetraoxa-2,8-diazatorizo-23-amino)thiazo-4-yl)-2-((carboxymethoxy)imino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 3, except that cefixime is used instead of ceftazidime. The yield of compound 8 was 38.7%.
[0074] 1 H NMR (400 MHz, DMSO- d 6) δ 12.81 (s, 1H), 12.26 (s, 1H), 12.03 (s,1H), 9.48 (s, 1H), 8.54 (s, 1H), 8.15 (s, 2H), 7.85 – 7.73 (m, 2H), 7.06 –6.65 (m, 3H), 6.33 (t, J = 3.4 Hz, 1H), 6.04 – 5.55 (m, 3H), 5.25 (d, J = 6.9 Hz, 1H), 5.03 (s, 1H), 4.82 (s, 2H), 4.14 – 4.07 (m, 1H), 3.76 – 3.54 (m, 18H), 3.31 – 3.16 (m, 3H), 2.61 (t, J= 5.9 Hz, 2H), 2.06 – 1.95 (m, 1H), 1.83 (s, 3H), 1.81 – 1.50 (m, 3H). 13 C NMR (101 MHz, DMSO- d 6) δ 179.77, 173.88, 171.37, 170.66, 167.54,167.31, 165.84, 161.85, 158.21, 146.64, 143.35, 130.29, 127.83, 126.53,124.47, 112.63, 70.69, 70.62, 70.41, 70.06, 69.76, 69.51, 69.07, 65.97,60.28, 60.09, 52.34, 37.85, 37.29, 36.46, 28.52, 28.18, 25.47, 22.01. Example 9 Compound 9: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20-tetraoxa-2,8-diazatorizo-23-amino)thiazo-4-yl)-2-((carboxymethoxy)imino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 4, only requiring the replacement of the corresponding raw materials. The yield of compound 9 was 14.3%.
[0075] 1 H NMR (400 MHz, DMSO- d 6) δ 12.82 (s, 1H), 12.59 (s, 1H), 12.39 (s,1H), 9.28 (s, 1H), 8.74 (s, 1H), 8.63 (s, 2H), 7.83 – 7.74 (m, 2H), 7.11 –6.74 (m, 3H), 6.32 (t, J = 3.4 Hz, 1H), 5.95 (dd, J = 16.7, 1.2 Hz, 1H), 5.84(dd, J= 8.1, 6.3 Hz, 1H), 5.62 (dd, J = 10.0, 1.8 Hz, 1H), 5.35 (d, J = 6.8 Hz,1H), 5.13 (s, 1H), 4.81 (s, 2H), 4.14 – 4.06 (m, 1H), 3.78 – 3.67 (m, 19H), 3.66 – 3.57 (m, 6H), 3.32 – 3.24 (m, 2H), 3.21 – 3.18 (m, 2H), 2.68 (t, J = 5.8Hz, 2H), 2.06 – 1.95 (m, 1H), 1.91 (s, 3H), 1.78 – 1.68 (m, 2H), 1.68 – 1.57(m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 170.77, 170.48, 170.38, 170.29, 167.94,167.31, 165.88, 161.87, 158.69, 146.65, 143.45, 130.19, 127.33, 126.52,124.71, 112.63, 70.79, 70.69, 70.61, 70.50, 69.71, 69.51, 69.09, 65.97,60.28, 60.03, 52.34, 41.93, 37.26, 37.08, 28.78, 28.03, 25.82, 22.43. Example 10 Compound 10: (6 R 7 R )-7-(( Z )-2-(2-(( S) Preparation of -6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26,29,32-octoxy-2,8-diazapentadecane-35-amino)thiazo-4-yl)-2-((carboxymethoxy)imino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid The preparation method is the same as in Example 5, except that cefixime is used instead of ceftazidime. The yield of compound 10 was 5.2%.
[0076] 1H NMR (400 MHz, DMSO- d 6) δ 9.87 (s, 1H), 8.67 (s, 1H), 8.15 (s, 2H), 7.79 – 7.68 (m, 2H), 7.17 – 6.77 (m, 3H), 6.38 (t, J = 3.3 Hz, 1H), 6.04 – 5.69(m, 3H), 5.26 – 4.95 (m, 2H), 4.83 (s, 2H), 4.15 – 4.01 (m, 1H), 3.84 – 3.57(m, 34H), 3.31 – 2.99 (m, 4H), 2.68 (t, J = 5.8 Hz, 2H), 2.16 – 1.99 (m, 3H), 1.94 (s, 3H), 1.81 – 1.47 (m, 3H). 13 C NMR (101 MHz, DMSO- d 6) δ 173.97, 173.28, 171.37, 170.69, 167.34,166.35, 165.44, 161.83, 158.22, 146.14, 143.35, 130.79, 127.86, 126.55,124.74, 112.43, 71.39, 70.69, 70.21, 70.00, 69.70, 69.51, 69.29, 65.97,60.28, 60.09, 52.34, 37.90, 37.53, 36.42, 28.74, 28.15, 25.35, 22.44. Example 11 Compound 11: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of oct-2-acetamido-5-(3-phosphonoguanidinyl)pentamido)thiazo-4-yl)-2-(methoxyimino)acetamido)-3-(acetoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid: The preparation method is the same as in Example 1, except that cefotaxime is used instead of ceftazidime. The yield of compound 11 was 88.1%.
[0077] 1 H NMR (400 MHz, DMSO-d 6) δ 12.49 (s, 1H), 8.77 (s, 1H), 8.24 (d, J =8.1 Hz, 1H), 8.13 (s, 2H), 7.96 (d, J = 8.2 Hz, 1H), 6.97 (s, 1H), 6.32 (t, J =3.3 Hz, 1H), 5.83 (dd, J = 8.1, 6.9 Hz, 1H), 5.22 (d, J = 6.8 Hz, 1H), 5.03 (s,1H), 4.99 (s, 2H), 4.36 – 4.28 (m, 1H), 3.96 (s, 3H), 3.62 (d, J = 15.2 Hz, 1H), 3.50 (d, J = 15.2 Hz, 1H), 3.28 – 3.17 (m, 2H), 2.30 (s, 3H), 2.07 (s,3H), 1.95 – 1.85 (m, 4H), 1.79 – 1.70 (m, 1H), 1.69 – 1.59 (m, 2H). 13 C NMR (101 MHz, DMSO- d 6) δ 191.92, 178.45, 173.16, 172.46, 167.30,167.01, 161.22, 159.34, 146.43, 141.75, 138.67, 121.47, 112.88, 64.49, 62.19,60.62, 59.40, 53.31, 37.96, 29.80, 28.46, 27.89, 25.95, 22.41, 19.85. Example 12 Compound 12: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14-dioxa-2,8-diazaheptadecane-17-amino)thiazo-4-yl)-2-(methoxyimino)acetamido)-3-(acetoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 2, except that cefotaxime is used instead of ceftazidime. The yield of compound 12 was 67.4%.
[0078] 1 H NMR (400 MHz, DMSO- d 6) δ 10.88 (s, 1H), 8.72 (s, 1H), 8.44 (d, J =8.1 Hz, 1H), 8.16 (s, 2H), 7.78 (d, J = 8.4 Hz, 1H), 7.13 – 6.88 (m, 2H), 6.30(t, J = 3.3 Hz, 1H), 5.86 (dd, J = 8.1, 6.9 Hz, 1H), 5.22 (d, J = 6.8 Hz, 1H), 5.03(s, 1H), 4.99 (s, 2H), 4.17 – 4.05 (m, 1H), 3.94 (s, 3H), 3.71 (t, J = 5.8 Hz,2H), 3.67 – 3.57 (m, 7H), 3.50 (d, J = 15.2 Hz, 1H), 3.32 – 3.24 (m, 2H), 3.21– 3.16 (m, 2H), 2.68 (t, J = 5.8 Hz, 2H), 2.30 (s, 3H), 2.07 (s, 2H), 2.03 –1.95 (m, 1H), 1.81 (s, 3H), 1.80 – 1.69 (m, 2H), 1.68 – 1.56 (m, 1H). 13 C NMR (101 MHz, DMSO- d6) δ 190.98, 178.05, 173.76, 171.33, 170.59,167.11, 167.05, 161.55, 158.99, 147.13, 142.11, 138.47, 121.42, 112.25,69.74, 69.53, 69.07, 65.07, 64.46, 62.01, 60.62, 59.45, 52.34, 37.90, 37.03,36.42, 28.69, 28.13, 27.36, 25.89, 22.48, 19.84. Example 13 Compound 13: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20-tetraoxa-2,8-diazatorizo-23-amino)thiazo-4-yl)-2-(methoxyimino)acetamido)-3-(acetoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 3, except that cefotaxime is used instead of ceftazidime. The yield of compound 13 was 38.1%.
[0079] 1 H NMR (400 MHz, DMSO- d 6) δ 12.79 (s, 1H), 9.89 (s, 1H), 8.78 (s, 1H), 8.23 (d, J = 8.1 Hz, 1H), 8.13 (s, 2H), 7.79 (d, J = 8.4 Hz, 1H), 7.02 – 6.95 (m,2H), 6.32 (t, J = 3.7 Hz, 1H), 5.83 (dd, J = 8.5, 6.9 Hz, 1H), 5.21 (d, J= 6.2 Hz,1H), 5.13 (s, 1H), 4.99 (s, 2H), 4.17 – 4.06 (m, 1H), 3.95 (s, 3H), 3.72 –3.67 (m, 10H), 3.66 – 3.62 (m, 4H), 3.61 – 3.58 (m, 3H), 3.50 (d, J = 15.0 Hz,1H), 3.32 – 3.26 (m, 2H), 3.25 – 3.19 (m, 2H), 2.68 (t, J = 5.9 Hz, 2H), 2.35(s, 3H), 2.06 (s, 2H), 2.04 – 1.94 (m, 1H), 1.86 (s, 3H), 1.81 – 1.70 (m,2H), 1.67 – 1.55 (m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 191.58, 178.45, 173.74, 172.33, 170.69,167.32, 167.20, 161.15, 158.25, 147.53, 142.41, 138.04, 121.32, 112.03,70.72, 70.61, 70.11, 69.70, 69.51, 69.09, 65.67, 64.42, 62.06, 60.67, 59.40,52.35, 37.82, 37.48, 36.06, 28.67, 28.29, 27.32, 25.67, 22.41, 19.84. Example 14 Compound 14: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26-hexaoxa-2,8-diazaeicosane-29-amino)thiazo-4-yl)-2-(methoxyimino)acetamido)-3-(acetoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 4, except that cefotaxime is used instead of ceftazidime. The yield of compound 14 was 22.6%.
[0080] 1 H NMR (400 MHz, DMSO- d 6) δ 12.69 (s, 1H), 9.81 (s, 1H), 8.72 (s, 1H), 8.25 (d, J = 8.7 Hz, 1H), 8.10 (s, 2H), 7.71 (d, J = 8.2 Hz, 1H), 7.05 – 6.92 (m,2H), 6.32 (t, J = 3.8 Hz, 1H), 5.43 (dd, J = 8.3, 6.8 Hz, 1H), 5.22 (d, J = 6.2 Hz,1H), 5.09 – 5.00 (m, 3H), 4.13 – 4.06 (m, 1H), 3.92 (s, 3H), 3.76 – 3.69 (m,15H), 3.68 – 3.59 (m, 10H), 3.50 (d, J = 15.2 Hz, 1H), 3.31 – 3.27 (m, 2H), 3.26 – 3.15 (m, 2H), 2.68 (t, J = 5.8 Hz, 2H), 2.30 (s, 3H), 2.07 (s, 2H), 2.03– 1.94 (m, 1H), 1.91 (s, 3H), 1.79 – 1.71 (m, 2H), 1.68 – 1.56 (m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 191.96, 178.01, 173.72, 171.58, 170.69,167.41, 167.01, 161.22, 158.20, 147.03, 142.11, 138.07, 121.42, 112.05,70.79, 70.69, 70.61, 69.70, 69.51, 69.09, 65.97, 64.42, 62.09, 60.67, 59.40,52.34, 37.90, 37.51, 36.68, 28.83, 28.49, 27.82, 25.94, 22.43, 19.86. Example 15 Compound 15: (6R 7 R )-7-(( Z )-2-(2-(( S Preparation of octyl-2-ene-2-carboxylic acid: 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26,29,32-octoxy-2,8-diazapentadecane-35-amino)thiazo-4-yl)-2-(methoxyimino)acetamido)-3-(acetoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]octyl-2-ene-2-carboxylic acid: The preparation method is the same as in Example 5, except that cefotaxime is used instead of ceftazidime. The yield of compound 15 was 9.3%.
[0081] 1 H NMR (400 MHz, DMSO- d 6) δ 12.29 (s, 1H), 9.84 (s, 1H), 8.76 (s, 1H), 8.35 – 8.08 (m, 3H), 7.77 (d, J = 7.9 Hz, 1H), 7.15 – 6.85 (m, 2H), 6.38 (t, J =3.8 Hz, 1H), 5.83 (dd, J = 8.0, 6.7 Hz, 1H), 5.22 (d, J = 6.4 Hz, 1H), 5.06 –5.01 (m, 3H), 4.12 – 4.04 (m, 1H), 3.96 (s, 3H), 3.92 – 3.67 (m, 25H), 3.66 –3.59 (m, 7H), 3.50 (d, J = 15.2 Hz, 1H), 3.31 – 3.20 (m, 4H), 2.68 (t, J = 5.2Hz, 2H), 2.30 (s, 3H), 2.07 (s, 3H), 2.05 – 1.98 (m, 1H), 1.92 (s, 3H), 1.80 – 1.69 (m, 2H), 1.65 – 1.57 (m, 1H). 13 C NMR (101 MHz, DMSO- d6) δ 191.98, 178.05, 173.77, 171.38, 170.69,167.31, 167.00, 161.25, 158.29, 147.03, 142.11, 138.07, 121.42, 112.05,70.79, 70.69, 70.61, 69.70, 69.51, 69.09, 65.97, 64.42, 62.09, 60.67, 59.40,52.34, 37.97, 37.44, 36.49, 28.86, 28.32, 27.74, 25.92, 22.58, 19.73. Example 16 Compound 16: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-5-(3-phosphonoguanidinyl)pentamido)thiazo-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid: The preparation method was the same as in Example 1, except that cefdinir was used instead of ceftazidime. The yield of compound 16 was 85.4%.
[0082] 1 H NMR (400 MHz, DMSO- d6 ) δ 13.52 (s, 1H), 12.52 (s, 1H), 12.42 (s,1H), 8.14 (s, 2H), 7.94 (d, J = 8.2 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.47 (s,1H), 6.93 – 6.85 (m, 1H), 6.32 (t, J = 3.3 Hz, 1H), 5.95 (dd, J = 16.3, 1.8 Hz, 1H), 5.84 (dd, J = 8.0, 6.8 Hz, 1H), 5.69 (dd, J = 10.9, 1.9 Hz, 1H), 5.35 (d, J =6.8 Hz, 1H), 5.03 (s, 1H), 4.38 – 4.29 (m, 1H), 3.74 (dd,J = 14.8, 0.9 Hz, 1H), 3.64 (dd, J = 14.8, 0.9 Hz, 1H), 3.27 – 3.16 (m, 2H), 1.95 – 1.86 (m, 4H), 1.80 – 1.71 (m, 1H), 1.69 – 1.59 (m, 2H). 13 C NMR (101 MHz, DMSO- d6 ) δ 173.12, 170.44, 167.64, 167.38, 166.50,165.84, 159.74, 142.91, 141.34, 130.15, 127.83, 126.52, 124.73, 111.24,64.28, 60.59, 53.61, 37.62, 28.80, 28.23, 25.95, 22.71. Example 17 Compound 17: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14-dioxa-2,8-diazaheptadecane-17-amino)thiazo-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 2, except that cefdinir is used instead of ceftazidime. The yield of compound 17 was 58.1%.
[0083] 1 H NMR (400 MHz, DMSO- d 6) δ 13.73 (s, 1H), 12.47 (s, 1H), 12.10 (s,1H), 9.96 (s, 1H), 8.75 (s, 1H), 8.63 (s, 2H), 7.82 – 7.71 (m, 2H), 7.47 (s,1H), 6.98 (t, J = 5.0 Hz, 1H), 6.90 – 6.83 (m, 1H), 6.32 (t, J = 3.3 Hz, 1H), 5.95 (dd, J= 16.3, 1.8 Hz, 1H), 5.84 (dd, J = 8.1, 6.8 Hz, 1H), 5.69 (dd, J =10.9, 1.9 Hz, 1H), 5.15 (d, J = 6.8 Hz, 1H), 4.92 (s, 1H), 4.13 – 4.06 (m, 1H), 3.77 – 3.69 (m, 3H), 3.67 – 3.58 (m, 7H), 3.30 – 3.17 (m, 4H), 2.68 (t, J = 5.8Hz, 2H), 2.04 – 1.94 (m, 1H), 1.91 (s, 3H), 1.79 – 1.69 (m, 2H), 1.66 – 1.55(m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 173.76, 171.33, 170.65, 167.44, 167.08,166.59, 165.04, 158.11, 142.50, 141.23, 130.13, 127.43, 126.57, 124.74,112.86, 69.71, 69.51, 69.09, 65.97, 60.28, 60.09, 52.34, 37.84, 37.43, 36.57,28.92, 28.36, 25.67, 22.39. Example 18 Compound 18: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20-tetraoxa-2,8-diazatorizo-23-amino)thiazo-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 3, except that cefdinir is used instead of ceftazidime. The yield of compound 18 was 32.1%.
[0084] 1 H NMR (400 MHz, DMSO- d6) δ 13.65 (s, 1H), 12.44 (s, 1H), 12.41 (s,1H), 8.76 (s, 1H), 8.25 (s, 2H), 8.22 (s, 1H), 7.85 – 7.72 (m, 2H), 7.58 (s,1H), 6.92 (t, J = 5.3 Hz, 1H), 6.89 – 6.82 (m, 1H), 6.32 (t, J = 3.6 Hz, 1H), 5.95 (dd, J = 16.2, 1.9 Hz, 1H), 5.84 (dd, J = 8.4, 6.9 Hz, 1H), 5.69 (dd, J =10.8, 1.7 Hz, 1H), 5.15 (d, J = 6.4 Hz, 1H), 5.03 (s, 1H), 4.40 (t, J = 5.1 Hz,2H), 4.14 – 4.06 (m, 1H), 3.76 (t, J = 5.3 Hz, 2H), 3.72 – 3.58 (m, 12H), 3.31– 3.16 (m, 4H), 2.05 – 1.99 (m, 1H), 1.96 (s, 3H), 1.78 – 1.74 (m, 2H), 1.69– 1.54 (m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 173.77, 170.69, 167.34, 167.01, 166.57,165.84, 158.32, 154.78, 142.82, 141.16, 130.19, 127.83, 126.50, 124.74,110.27, 70.75, 70.61, 70.46, 69.70, 69.09, 68.57, 63.95, 60.28, 60.09, 52.34,37.86, 37.46, 28.53, 28.26, 25.47, 22.52. Example 19 Compound 19: (6 R 7 R )-7-(( Z )-2-(2-((S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26-hexaoxa-2,8-diazaeicosane-29-amino)thiazo-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 4, except that cefdinir is used instead of ceftazidime. The yield of compound 19 was 13.9%.
[0085] 1 H NMR (400 MHz, DMSO- d 6) δ 13.72 (s, 1H), 12.76 (s, 1H), 12.40 (s,1H), 9.96 (s, 1H), 8.77 (s, 1H), 8.13 (s, 2H), 7.87 – 7.74 (m, 2H), 7.03 (s,1H), 6.94 (t, J = 5.9 Hz, 1H), 6.90 – 6.85 (m, 1H), 6.32 (t, J = 3.3 Hz, 1H), 5.95 (dd, J = 16.1, 1.9 Hz, 1H), 5.84 (dd, J = 8.8, 6.0 Hz, 1H), 5.69 (dd, J =10.5, 1.7 Hz, 1H), 5.15 (d, J = 6.2 Hz, 1H), 5.11 (s, 1H), 4.13 – 4.08 (m, 1H), 3.75 – 3.58 (m, 25H), 3.31 – 3.18 (m, 4H), 2.68 (t, J = 5.8 Hz, 2H), 2.03 –1.94 (m, 1H), 1.93 (s, 3H), 1.79 – 1.68 (m, 2H), 1.67 – 1.55 (m, 1H). 13 C NMR (101 MHz, DMSO- d6) δ 173.74, 171.28, 170.09, 168.32, 167.35,166.54, 165.84, 158.14, 142.92, 141.33, 130.19, 127.83, 126.50, 124.74,110.86, 70.79, 70.69, 70.61, 69.70, 69.51, 69.19, 65.97, 63.25, 63.09, 52.34,37.89, 37.46, 36.49, 28.83, 28.12, 25.73, 22.64. Example 20 Compound 20: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of octyl-6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26,29,32-octoxy-2,8-diazapentadecane-35-amino)thiazo-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]octyl-2-ene-2-carboxylic acid: The preparation method is the same as in Example 5, except that cefdinir is used instead of ceftazidime. The yield of compound 20 was 7.4%.
[0086] 1 H NMR (400 MHz, DMSO- d 6) δ 13.56 (s, 1H), 12.76 (s, 1H), 12.46 (s,1H), 10.32 (s, 1H), 9.76 (s, 1H), 8.43 (s, 2H), 7.89 – 7.74 (m, 2H), 7.49 (s,1H), 6.94 – 6.86 (m, 2H), 6.32 (t, J = 3.0 Hz, 1H), 5.95 (dd, J = 16.6, 1.9 Hz, 1H), 5.84 (dd, J = 8.2, 6.6 Hz, 1H), 5.69 (dd, J = 10.2, 1.8 Hz, 1H), 5.15 (d, J=6.4 Hz, 1H), 5.10 (s, 1H), 4.14 – 4.05 (m, 1H), 3.76 – 3.67 (m, 27H), 3.66 –3.58 (m, 7H), 3.31 – 3.17 (m, 4H), 2.68 (t, J = 5.8 Hz, 2H), 2.07 – 1.93 (m,1H), 1.81 (s, 3H), 1.79 – 1.69 (m, 2H), 1.68 – 1.54 (m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 173.67, 171.29, 170.57, 167.74, 167.39,166.51, 165.83, 158.12, 142.17, 141.83, 130.59, 127.84, 126.52, 124.77,115.56, 71.71, 70.79, 70.61, 69.76, 69.57, 69.19, 65.99, 60.28, 60.19, 52.34,37.85, 37.26, 36.59, 28.71, 28.36, 25.61, 22.54. Example 21 Compound 21: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-5-(3-phosphonoguanidinyl)pentamido)thiazo-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid: The preparation method is the same as in Example 1, except that ceftazidime is replaced with cefazolin. The yield of compound 21 was 90.1%.
[0087] 1 H NMR (400 MHz, DMSO- d 6) δ 12.66 (s, 1H), 12.42 (s, 1H), 8.47 (s,1H), 8.23 (s, 2H), 7.89 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 8.1 Hz, 1H), 6.97 (s,1H), 6.45 (t,J = 4.4 Hz, 1H), 6.32 (t, J = 3.3 Hz, 1H), 5.65 (dd, J = 8.1, 6.3 Hz, 1H), 5.18 (d, J = 6.4 Hz, 1H), 5.12 (s, 1H), 4.48 – 4.43 (m, 1H), 3.96 (s, 3H), 3.55 – 3.39 (m, 2H), 3.27 – 3.16 (m, 2H), 1.95 – 1.86 (m, 4H), 1.80 – 1.70 (m, 1H), 1.69 – 1.59 (m, 2H). 13 C NMR (101 MHz, DMSO- d 6) δ 173.10, 170.45, 169.34, 168.52, 167.31,161.45, 159.91, 146.94, 141.67, 136.47, 116.85, 112.58, 62.19, 60.40, 58.56,53.31, 37.99, 28.81, 28.42, 25.35, 22.49. Example 22 Compound 22: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14-dioxa-2,8-diazaheptadecane-17-amino)thiazo-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 2, except that ceftazidime is replaced with cefazolin. The yield of compound 22 was 61.1%.
[0088] 1 H NMR (400 MHz, DMSO- d 6) δ 13.69 (s, 1H), 9.88 (s, 1H), 8.67 (s, 1H), 8.13 (s, 2H), 7.83 – 7.73 (m, 2H), 7.05 – 6.85 (m, 2H), 6.55 (t, J= 4.4 Hz, 1H), 6.32 (t, J = 3.3 Hz, 1H), 5.85 (dd, J = 8.1, 6.3 Hz, 1H), 5.18 (d, J = 6.4 Hz,1H), 5.11 (s, 1H), 4.15 – 4.06 (m, 1H), 4.02 (s, 3H), 3.71 (t, J = 5.8 Hz, 2H), 3.66 – 3.58 (m, 6H), 3.50 (dd, J = 15.2, 4.4 Hz, 1H), 3.39 (dd, J = 15.4, 4.4 Hz,1H), 3.31 – 3.18 (m, 4H), 2.68 (t, J = 5.8 Hz, 2H), 2.06 – 1.94 (m, 1H), 1.90 (s, 3H), 1.81 – 1.68 (m, 2H), 1.66 – 1.54 (m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 173.89, 171.43, 170.52, 169.22, 168.42,167.32, 161.55, 158.79, 147.63, 142.11, 136.64, 116.19, 112.45, 69.71, 69.41,69.32, 65.78, 62.09, 60.40, 58.64, 52.14, 37.83, 37.51, 36.69, 29.07, 28.53,25.62, 22.51. Example 23 Compound 23: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20-tetraoxa-2,8-diazatorizo-23-amino)thiazo-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 3, except that ceftazidime is replaced with cefazolin. The yield of compound 23 was 42.7%.
[0089] 1 H NMR (400 MHz, DMSO- d 6) δ 12.69 (s, 1H), 12.56 (s, 1H), 10.78 (s,1H), 9.67 (s, 1H), 8.73 (s, 2H), 7.86 – 7.75 (m, 2H), 7.06 – 6.84 (m, 2H), 6.55 (t, J = 4.8 Hz, 1H), 6.32 (t, J = 3.5 Hz, 1H), 5.85 (dd, J = 8.7, 6.2 Hz, 1H), 5.48 (d, J = 6.7 Hz, 1H), 5.33 (s, 1H), 4.16 – 4.04 (m, 1H), 4.01 (s, 3H), 3.75 – 3.67 (m, 10H), 3.66 – 3.57 (m, 6H), 3.50 (dd, J = 15.0, 4.2 Hz, 1H), 3.39(dd, J = 15.9, 4.1 Hz, 1H), 3.30 – 3.19 (m, 4H), 2.68 (t, J = 5.2 Hz, 2H), 2.07 –1.94 (m, 1H), 1.91 (s, 3H), 1.81 – 1.69 (m, 2H), 1.67 – 1.56 (m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 174.77, 173.38, 172.67, 169.64, 167.51,166.81, 165.25, 161.29, 147.93, 144.11, 136.44, 116.15, 112.05, 70.79, 70.69,70.61, 69.70, 69.51, 69.09, 65.97, 62.09, 60.40, 58.52, 52.34, 37.74, 37.16,36.60, 28.76, 28.49, 25.77, 22.50. Example 24 Compound 24: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of 6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26-hexaoxa-2,8-diazaeicosane-29-amino)thiazo-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid: The preparation method is the same as in Example 4, except that ceftazidime is replaced with cefazolin. The yield of compound 24 was 21.8%.
[0090] 1 H NMR (400 MHz, DMSO- d6 ) δ 12.47 (s, 1H), 12.43 (s, 1H), 11.28 (s,1H), 9.77 (s, 1H), 8.43 (s, 2H), 7.83 – 7.70 (m, 2H), 7.13 – 6.87 (m, 2H), 6.55 (t, J = 4.3 Hz, 1H), 6.32 (t, J = 3.9 Hz, 1H), 5.85 (dd, J = 8.5, 6.2 Hz, 1H), 5.18 (d, J = 6.6 Hz, 1H), 5.03 (s, 1H), 4.15 – 4.04 (m, 1H), 3.82 (s, 3H), 3.73 – 3.67 (m, 18H), 3.67 – 3.57 (m, 6H), 3.50 (dd, J = 15.9, 4.0 Hz, 1H), 3.46 –3.37 (m, 1H), 3.33 – 3.28 (m, 2H), 3.27 – 3.17 (m, 2H), 2.68 (t, J = 5.2 Hz,2H), 2.04 – 1.95 (m, 1H), 1.88 (s, 3H), 1.80 – 1.68 (m, 2H), 1.65 – 1.58 (m,1H). 13 C NMR (101 MHz, DMSO- d6) δ 174.75, 173.32, 171.68, 169.74, 168.92,167.31, 161.85, 160.29, 157.67, 153.21, 136.44, 116.15, 112.05, 70.79, 70.69,70.61, 69.70, 69.51, 69.09, 65.97, 62.09, 60.40, 58.52, 52.34, 37.96, 37.82,36.58, 28.84, 28.32, 25.83, 22.68. Example 25 Compound 25: (6 R 7 R )-7-(( Z )-2-(2-(( S Preparation of octyl-6-acetamido-1-imino-7-oxo-1-(phosphonoamino)-11,14,17,20,23,26,29,32-octoxy-2,8-diazapentadecane-35-amino)thiazo-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]octyl-2-ene-2-carboxylic acid: The preparation method is the same as in Example 5, except that ceftazidime is replaced with cefazolin. The yield of compound 25 was 8.7%.
[0091] 1 H NMR (400 MHz, DMSO- d 6) δ 12.65 (s, 1H), 12.21 (s, 1H), 10.03 (s,1H), 9.27 (s, 1H), 9.13 (s, 2H), 7.72 – 7.61 (m, 2H), 7.01 – 6.95 (m, 2H), 6.55 (t, J = 4.4 Hz, 1H), 6.32 (t, J = 3.3 Hz, 1H), 5.85 (dd, J = 7.9, 6.1 Hz, 1H), 5.18 (d, J = 6.2 Hz, 1H), 5.11 (s, 1H), 4.14 – 4.08 (m, 1H), 3.76 (s, 3H), 3.73 – 3.66 (m, 26H), 3.65 – 3.59 (m, 6H), 3.50 (dd, J= 15.5, 4.9 Hz, 1H), 3.39(dd, J = 15.0, 4.7 Hz, 1H), 3.32 – 3.19 (m, 4H), 2.68 (t, J = 5.8 Hz, 2H), 2.03 –1.93 (m, 1H), 1.92 (s, 3H), 1.80 – 1.70 (m, 2H), 1.66 – 1.56 (m, 1H). 13 C NMR (101 MHz, DMSO- d 6) δ 174.34, 173.38, 170.56, 169.78, 168.42,165.31, 161.75, 158.69, 148.03, 146.19, 134.74, 118.15, 116.45, 70.52, 70.45,70.31, 69.78, 69.51, 68.79, 66.97, 65.09, 63.41, 58.52, 56.34, 47.95, 37.80,34.58, 28.79, 28.42, 25.90, 22.49. II. In vitro antibacterial activity assay According to the Clinical and Laboratory Standards Institute (CLSI) guidelines, using ceftazidime, cefixime, cefotaxime, cefdinir, and ceftizoxime as positive controls, the minimum inhibitory concentration (MIC) of cephalosporin bacterial degrading agents was determined using the microbroth dilution method.
[0092] The experimental strains included Gram-positive bacteria: *Staphylococcus aureus* ATCC 25923, *Bacillus subtilis* ATCC 6633, *Staphylococcus epidermidis* ATCC 12228, methicillin-resistant *Staphylococcus aureus* ATCC 43300, multidrug-resistant *Staphylococcus aureus* 171, and vancomycin-resistant *Enterococcus faecalis* 80; and Gram-negative bacteria: *Acinetobacter baumannii* ATCC 19606, *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, *Salmonella enterica* ATCC 14028, multidrug-resistant *Pseudomonas aeruginosa* 264, carbapenem-resistant *Escherichia coli* 361, and multidrug-resistant *Acinetobacter baumannii* 183. The above-mentioned standard control strains were purchased from ATCC, while the remaining strains were clinically isolated drug-resistant strains provided by the Institute of Antibiotics, Huashan Hospital, Fudan University, and were used after identification using standard methods.
[0093] The specific operating steps are as follows: (1) Preparation of culture medium Prepare MHB culture medium to a total volume of 1 L according to the product instructions, dispense into Erlenmeyer flasks, autoclave at 121℃ for 15 min, and cool before use (MHB culture medium was purchased from Qingdao High-tech Industrial Park Haibo Biotechnology Co., Ltd.).
[0094] (2) Sample solution preparation Weigh the cephalosporin bacterial degradation agent sample to be tested, dissolve it in distilled water and prepare a sample solution of 5.12 mg / mL; treat the positive control in the same way and prepare a solution of 5.12 mg / mL for later use.
[0095] (3) Preparation of bacterial suspension ① Thaw the glycerol cryovials of the experimental strains rapidly at 37°C, take 1 mL of bacterial culture and inoculate it into 50 mL of sterilized and cooled to room temperature MHB medium, and culture it in a shaker at 37°C for 16-20 h; the next day, transfer it to fresh MHB medium at a ratio of 1:50 and culture it in a shaking culture at 37°C until the logarithmic growth phase.
[0096] ② Under aseptic conditions, the experimental strains cultured to the logarithmic growth phase were corrected to the 0.5 McFarland unit turbidity standard (1.5 × 10⁻⁶ units) using MHB medium. 8 (CFU / mL), then diluted 100-fold to obtain approximately 1×10⁻⁶ CFU / mL. 6 CFU / mL bacterial suspension, for later use.
[0097] (4) Determination of MIC by twofold dilution of microbroth Take a sterile 96-well plate, add 10 μL of the test compound solution to each well, and obtain a concentration gradient by two-fold serial dilution. A positive control and a drug-free growth control group are also set up. Then, add 190 μL of the diluted bacterial suspension to each well, and incubate the 96-well plate in a 37°C humidity-controlled incubator for 20 h.
[0098] (5) MIC endpoint interpretation Add 20 μL of 0.01% resazurin indicator solution to each well of the 96-well plate after incubation. Continue incubation at 37°C for 1–2 hours. Observe the results when the drug-free growth control well turns from blue to pink. The lowest drug concentration that does not change color (remains blue) as observed by the naked eye is the MIC value of the compound.
[0099] Table 1. Minimum inhibitory concentration (μg / mL) of the test drug against standard control strains
[0100] Table 2. Minimum inhibitory concentrations (μg / mL) of the tested drugs against drug-resistant strains
[0101] The MIC results are shown in Tables 1 and 2. Figures 1-5 As shown, the cephalosporin-based bacterial degrading agents synthesized in this invention retain the overall antibacterial activity of the cephalosporin backbone and exhibit significantly improved activity compared to the positive control drugs ceftazidime, cefixime, cefotaxime, cefdinir, or cefazolin in some drug-resistant strains. Standard control strain testing results show that most compounds exhibit varying degrees of antibacterial activity against both Gram-positive and Gram-negative bacteria. Compounds 12, 17, 22, and 24 showed particularly strong performance in standard strains, indicating that the introduction of linkers and recruiting ligands did not completely disrupt the key pharmacodynamic structure of the cephalosporin nucleus. In contrast, compounds 5, 10, 20, and 25 showed weaker overall activity, suggesting that the linkage mode, spatial distance, and physicochemical properties of bifunctional molecules have a significant impact on antibacterial activity.
[0102] Among drug-resistant strains, the MICs of ceftazidime, cefixime, cefotaxime, cefdinir, or cefazolin against MRSA, MDRSA, VREfs, MDRPA, CR-EC, and MDRAB ranged from 32 to >128 μg / mL, indicating a significant decrease in the activity of traditional cephalosporins against multidrug-resistant bacteria. In contrast, several compounds in this series showed varying degrees of activity recovery. Compound 12, with MICs of 1, 4, and 8 μg / mL against MDRPA, CR-EC, and MDRAB, respectively, representing a 32-, 16-, and 16-fold reduction compared to ceftazidime, is the most representative compound with the most prominent activity against drug-resistant Gram-negative bacteria in this series. Compound 17, with MICs of 1 and 2 μg / mL against MRSA ATCC 43300 and MDRSA-171, respectively, representing a 128- and 64-fold reduction compared to ceftazidime, is the representative compound with the best activity against drug-resistant Gram-positive bacteria in this series. The above results indicate that bifunctional bacterial degraders based on cephalosporin backbones can significantly improve antibacterial activity in certain drug-resistant bacteria, providing experimental basis for subsequent verification of target protein degradation mechanisms and development of drugs against drug-resistant infections.
[0103] III. Detection of PBP2a protein expression level To investigate the degradation ability of the compounds of this invention on penicillin-binding protein 2a (PBP2a) in the target strain, Western blotting (WB) was used to detect the changes in PBP2a protein expression in methicillin-resistant Staphylococcus aureus ATCC43300 before and after administration of compound 17.
[0104] The specific operating steps are as follows: (1) Cell treatment: Under aseptic conditions, the experimental strains in the logarithmic growth phase were inoculated into MHB medium containing different concentrations of the test compounds and incubated at 37°C for 4 h; then centrifuged at 4°C and 6000 rpm for 10 min to collect the cells, washed twice with pre-cooled PBS buffer, discarded the supernatant, and collected the precipitate for later use.
[0105] (2) Extraction of total cell protein: Add an appropriate amount of lysis buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100] to the bacterial pellet, and pre-add a protease inhibitor cocktail, 1 mM PMSF, and lysostaphin (final concentration 100 μg / mL). Incubate at 37°C for 30 min until the bacterial solution is clear. Then add MgCl2 and BeyoZonase nuclease to reduce the viscosity of the lysis buffer. Centrifuge at 4°C, 6000 rpm for 15 min, and collect the supernatant, which is the total cell protein.
[0106] (3) Protein quantification and sample preparation: The protein concentration of the supernatant was determined using the BCA protein quantification kit. Based on the quantification results, 5×SDS loading buffer was added and the volume was made up with lysis buffer to make the total protein concentration of each group consistent. The samples were placed in a 95℃ metal bath for 10 min to denature them for later use.
[0107] (4) SDS-PAGE electrophoresis: Prepare a 10% SDS-PAGE separating gel and add 25 μL of denatured protein sample to each well. At the same time, set up a normal bacterial growth control group, a control drug PBP / transpeptidase inhibitor ceftazidime (100 μg / mL) treatment group, and a color-prestained protein marker as a molecular weight reference; perform stacking gel electrophoresis at 80 V, and after the sample enters the separating gel, adjust the voltage to 120 V until the bromophenol blue indicator reaches the bottom of the gel.
[0108] (5) Transfer and blocking: The protein was transferred from the gel to the pre-activated PVDF membrane by wet transfer (4℃, 300 mA constant current, transfer for 90 min); after the transfer was completed, the membrane was immersed in TBST blocking solution containing 5% skim milk powder and blocked by shaking at room temperature for 2 h to eliminate non-specific binding.
[0109] (6) Antibody incubation: The membrane was placed in primary antibody dilution buffer [Mouse monoclonal anti-PBP2a antibody (Sigma-Aldrich, Cat# SAB4200853), 1:1000 dilution] and incubated overnight at 4°C with shaking. The next day, the membrane was washed three times with TBST buffer at room temperature with shaking for 10 min each time to remove free primary antibody. Then, HRP-labeled goat anti-mouse IgG secondary antibody (1:5000 dilution) was added and incubated at room temperature in the dark with shaking for 2 h. The washing steps were repeated to remove free secondary antibody. Note: GAPDH was used as an internal control for the above incubation steps.
[0110] (7) Development and data analysis: ECL chemiluminescent substrate solution A and solution B were mixed in a 1:1 ratio and uniformly coated on a PVDF membrane. Exposure imaging was performed using a chemiluminescence imaging system. The grayscale of the protein bands was analyzed using ImageJ image analysis software, and the grayscale ratio of the target protein to the internal control was calculated as the relative expression level, thereby evaluating the degradation effect of the test compound on PBP2a protein.
[0111] Western blot results showed that in MRSA ATCC 43300, the intensity of the PBP2a protein band after treatment with the non-degradable control drug cefdinir (100 μg / mL) was not significantly different from that in the untreated control group, indicating that conventional cephalosporins mainly inhibit PBP enzyme activity rather than directly reducing PBP2a protein levels. In contrast, the PBP2a protein band was significantly weakened after treatment with compound 17, showing a concentration-dependent decreasing trend. Gray-scale quantification results showed that compound 17 significantly reduced the relative protein level of PBP2a, with the most significant decrease observed in the high-concentration treatment group. Figure 6 This result is consistent with the low MIC activity of compound 17 against MRSA and MDRSA, demonstrating that in addition to retaining the PBP binding ability of cephalosporins, it may also induce a decrease in PBP2a protein levels. These results provide experimental support for the bacterial protein degrading agent strategy targeting penicillin-binding proteins in this invention.
[0112] The above content is only for illustrating the technical concept of the present invention and should not be construed as limiting the scope of protection of the present invention. Any modifications made to the technical solution based on the technical concept proposed in this invention shall fall within the scope of protection of this invention.
Claims
1. A cephalosporin-based bacterial degrading agent, characterized in that, The compound is a compound of Formula I or a pharmaceutically acceptable salt thereof, and a solvent compound, enantiomer, diastereomer, or mixture thereof in any proportion thereof, including racemic mixtures; the structural formula of the compound of Formula I is: Wherein, the structural formula of A is The structural formula of L is n = 2, 4, 6 or 8, m = 0 or 1, R is a cephalosporin compound containing aminothiazole, and the amino group on the aminothiazole ring of R is amide bonded to the acyl carbonyl group of A or L.
2. The cephalosporin-based bacterial degrading agent according to claim 1, characterized in that, The cephalosporin compound containing aminothiazole is selected from the following compounds: 。 3. A method for preparing a cephalosporin-type bacterial degrading agent as described in claim 1 or 2, characterized in that, When m=1, the preparation method of cephalosporin bacterial degrading agent is as follows: using N-benzyloxycarbonyl-L-arginine as raw material, benzyl bromide is used to protect its carboxyl group to obtain compound I; Compound I was phosphorylated to give compound II; Under acidic conditions, the protecting group on compound II was removed by passing palladium on carbon and hydrogen gas to obtain compound III; The α-amino group on compound III was protected with fluorenemethyloxycarbonyl chloride to obtain compound IV; compound IV was then reacted with Linker via an amide condensation reaction to obtain compound a; Compound a was deprotected by removing the terminal tert-butyl protecting group to obtain compound b; the terminal carboxyl group of compound b underwent an amide condensation reaction with a cephalosporin compound containing aminothiazole to obtain compound c; Compound c was deprotected by removing the Fmoc protecting group from the amino group on its side chain to obtain compound d; the α-amino group of the arginine side chain in compound d formed an amide bond with acetic anhydride to obtain compound e; the trichloroethyl protecting group was removed under Pd / C and hydrogen conditions to obtain a cephalosporin-type bacterial degrading agent; Among them, compound I is Compound II is Compound III is Compound IV is Linker is Compound a is Compound b is Compound C is Compound d is Compound e is n = 2, 4, 6 or 8.
4. The method for preparing a cephalosporin-type bacterial degrading agent according to claim 3, characterized in that, In the synthesis of compound II, bis(trichloroethyl)phosphoryl chloride was used for phosphorylation. The molar ratio of compound IV to linker was 1:1.
1. In the synthesis of compound a, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate was added for activation. The molar ratio of compound b to cephalosporin compounds containing aminothiazole was 1:1.
1.
5. A method for preparing a cephalosporin-type bacterial degrading agent as described in claim 1 or 2, characterized in that, When m=0, the preparation method of cephalosporin bacterial degrading agent is as follows: using N-benzyloxycarbonyl-L-arginine as raw material, benzyl bromide is used to protect its carboxyl group to obtain compound I; Compound I was phosphorylated to give compound II; Under acidic conditions, the protecting group on compound II was removed by passing palladium on carbon and hydrogen gas to obtain compound III; Compound IV was obtained by protecting the α-amino group on compound III with fluorenemethyloxycarbonyl chloride; Compound IV undergoes amide condensation with a cephalosporin compound containing aminothiazole to give compound c; compound c is deprotected by the Fmoc protecting group to give compound d; the α-amino group of the arginine side chain in compound d forms an amide bond with acetic anhydride to give compound e; the trichloroethyl protecting group is removed under Pd / C and hydrogen conditions to give a cephalosporin-based bacterial degrading agent. Among them, compound I is Compound II is Compound III is Compound IV is Compound C is Compound d is Compound e is .
6. The use of the cephalosporin-type bacterial degrading agent as described in claim 1 or 2 in the preparation of anti-infective drugs.
7. The application according to claim 6, characterized in that, The infection is caused by pathogenic microorganisms, which are Gram-positive bacteria, Gram-negative bacteria, or clinically drug-resistant bacteria.
8. The application according to claim 6, characterized in that, The infections described are caused by Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC 6633, Staphylococcus epidermidis ATCC 12228, methicillin-resistant Staphylococcus aureus ATCC 43300, multidrug-resistant Staphylococcus aureus 171, vancomycin-resistant Enterococcus faecalis 80, Acinetobacter baumannii ATCC 19606, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Salmonella enterica ATCC 14028, multidrug-resistant Pseudomonas aeruginosa 264, carbapenem-resistant Escherichia coli 361, or multidrug-resistant Acinetobacter baumannii 183.
9. The application according to claim 6, characterized in that, The dosage form of the drug is for use alone or in combination with other related drugs, or mixed with pharmaceutically acceptable excipients and diluents to form tablets, capsules, granules, syrups, premixes or micro-pellets for oral administration, or to form liniments or injections for non-oral administration.
10. A pharmaceutical composition, characterized in that, The cephalosporin-type bacterial degrading agent as described in claim 1 or 2 is used as the active ingredient.
